Scarica l'app Stockscreener
16.39
2.79%
-0.47
Dopo l'orario di chiusura:
16.39
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TNDM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$16.86
Aprire:
$16.67
Volume 24 ore:
1.08M
Relative Volume:
0.70
Capitalizzazione di mercato:
$1.13B
Reddito:
$796.00M
Utile/perdita netta:
$-136.49M
Rapporto P/E:
-7.8421
EPS:
-2.09
Flusso di cassa netto:
$-64.24M
1 W Prestazione:
-3.76%
1M Prestazione:
-19.22%
6M Prestazione:
-51.95%
1 anno Prestazione:
-46.14%
Intervallo 1D:
$15.95
$16.76
Intervallo di 1 settimana:
$15.95
$17.73
Portata 52W:
$15.75
$53.69
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Nome
Tandem Diabetes Care Inc
Settore
Industria
Telefono
858-366-6900
Indirizzo
12400 HIGH BLUFF DRIVE, San Diego, CA
Confronta TNDM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
16.39 | 1.13B | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
129.89 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
93.58 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
339.59 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
81.80 | 104.24B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
69.20 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-10 | Iniziato | Mizuho | Neutral |
| 2025-03-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Downgrade | Citigroup | Buy → Neutral |
| 2025-03-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Iniziato | Bernstein | Outperform |
| 2024-10-04 | Iniziato | Goldman | Neutral |
| 2024-10-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-22 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Iniziato | Canaccord Genuity | Buy |
| 2024-05-30 | Iniziato | Redburn Atlantic | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-04-29 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Aggiornamento | Stifel | Hold → Buy |
| 2023-08-04 | Downgrade | Citigroup | Buy → Neutral |
| 2023-05-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-01-26 | Iniziato | Wolfe Research | Peer Perform |
| 2022-11-15 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-08-09 | Downgrade | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Underweight |
| 2020-12-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Iniziato | Wells Fargo | Overweight |
| 2020-07-31 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-07-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-06-18 | Reiterato | Raymond James | Outperform |
| 2020-04-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-03-05 | Iniziato | Citigroup | Neutral |
| 2020-02-06 | Iniziato | Raymond James | Outperform |
| 2020-02-04 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Iniziato | Guggenheim | Buy |
| 2019-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2019-05-17 | Reiterato | BofA/Merrill | Neutral |
| 2019-05-13 | Iniziato | SVB Leerink | Outperform |
| 2019-03-08 | Iniziato | BMO Capital Markets | Outperform |
| 2019-03-05 | Reiterato | BofA/Merrill | Neutral |
| 2019-02-27 | Reiterato | Lake Street | Buy |
| 2018-11-21 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Reiterato | Dougherty & Company | Buy |
| 2018-09-26 | Reiterato | Piper Jaffray | Overweight |
Mostra tutto
Tandem Diabetes Care Inc Borsa (TNDM) Ultime notizie
When the Price of (TNDM) Talks, People Listen - news.stocktradersdaily.com
Reasons to Hold TNDM Stock in Your Portfolio for Now - MSN
Press Release Distribution & PR Platform - ACCESS Newswire
RBC Capital Adjusts Tandem Diabetes (TNDM) Price Target Before Q - GuruFocus
RBC Cuts Price Target on Tandem Diabetes Care to $45 From $55, Keeps Outperform Rating - marketscreener.com
Q4 Earnings Outperformers: Tandem Diabetes (NASDAQ:TNDM) And The Rest Of The Healthcare Technology Stocks - Yahoo Finance
Mizuho Initiates Coverage of Tandem Diabetes Care (LSE:0M0F) with Neutral Recommendation - Nasdaq
Tandem Diabetes Care (TNDM) Moves 7.6% Higher: Will This Strength Last? - Yahoo Finance
Mizuho Initiates Coverage of Tandem Diabetes Care (TNDM) with Neutral Recommendation - Nasdaq
Forecasting The Future: 9 Analyst Projections For Tandem Diabetes Care - Benzinga
Mizuho Initiates Tandem Diabetes Care at Neutral With $20 Price Target - marketscreener.com
Mizuho sets Tandem Diabetes stock at Neutral with $20 target By Investing.com - Investing.com Canada
Mizuho Initiates Coverage of Tandem Diabetes (TNDM) with Neutral Rating | TNDM Stock News - GuruFocus
Tubeless Insulin Pump Market Set to Witness Significant Growth - openPR.com
SEC Form DEF 14A filed by Tandem Diabetes Care Inc. - Quantisnow
Diabetes Management Technologies Market Size, Report by 2034 - Precedence Research
INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Tandem Diabetes Care, Inc.(TNDM) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry - Benzinga
Tandem Diabetes Care stock hits 52-week low at $17.61 By Investing.com - Investing.com Australia
Tandem Diabetes Care To Announce First Quarter 2025 Financial Results - MarketScreener
Diabetes Tech Giant Tandem to Reveal Q1 Performance: Key Metrics Coming April 30 - Stock Titan
Medical Device Industry: Swept Up in the Tariffs, Diabetes Device Makers Bear the Brunt - Morningstar
Tandem Diabetes Care stock hits 52-week low at $17.61 - Investing.com
(TNDM) Investment Analysis - news.stocktradersdaily.com
Prudential Financial Inc. Purchases 39,784 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - MarketBeat
Tandem eyes Medicare coverage expansion for Type 2 - Yahoo Finance
Tandem Diabetes Care (TNDM) Down 8.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Artificial Pancreas Device System Market Projected To Witness - openPR
Tandem Diabetes Care Insiders Sell US$1.5m Of Stock, Possibly Signalling Caution - simplywall.st
Tandem Diabetes Care Inc (TNDM) Stock Price Down 4.6% on Mar 26 - GuruFocus
3 Reasons to Sell TNDM and 1 Stock to Buy Instead - Yahoo Finance
TNDM Stock Gains on the Commercial Launch of Control-IQ+ Technology - MSN
Stifel maintains Tandem Diabetes Care stock Buy rating, $60 target By Investing.com - Investing.com UK
(TNDM) Long Term Investment Analysis - Stock Traders Daily
Tandem Diabetes Gains 45.7% in a Year: What's Driving the Stock? - MSN
Tandem Diabetes at Oppenheimer Conference: Strategic Growth Insights - Investing.com
Tandem Diabetes at Oppenheimer Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Tandem announces publication of results from trial of Control-IQ+ AID technology - Yahoo Finance
Dexcom shares 15-day CGM data; Tandem posts Type 2 pivotal data - Yahoo Finance
Tandem’s Control-IQ+ looks like a smart move for insulin-using T2D - BioWorld MedTech
Tandem reports A1C reduction in type 2 diabetes study By Investing.com - Investing.com South Africa
Tandem Diabetes Launches Next-Gen Automated Insulin Delivery Algorithm in U.S. - MPO-mag
Tandem reports A1C reduction in type 2 diabetes study - Investing.com India
Tandem Diabetes Care Announces NEJM Publication of Positive Pivotal Study Outcomes with Control-IQ+ AID Technology in Type 2 Diabetes - Business Wire
Automated Insulin Delivery System Helps in Type 2 Diabetes - Medscape
Tubeless Insulin Pump Market Is Booming Worldwide | Medtronic - openPR
Tandem Diabetes Care launches Control-IQ+ automated insulin delivery technology in the US - Marketscreener.com
Tandem Diabetes Care Launches New Control-IQ+ Automated Insulin Delivery Technology in the United States - Enid News & Eagle
Tandem Diabetes Care Inc Azioni (TNDM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):